Tokyo, Feb. 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060733) titled 'A Study on the Significance of Combining Kampo Medicine with the Molecular Targeted Drug Lenvatinib for Unresectable Thyroid Cancer and Related Drug Interactions' on Feb. 28.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - No treatment
Primary Sponsor:
Institute - Ito Hospital
Condition:
Condition - Thyroid cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the significance of combining Kampo medicine with supportive therapy during lenvatinib treatment for unresectable advanced thyroid cancer
Basic objectives2 - Others
Intervention:
Interventions/Control_1 - Combined use of Kampo medicine
Interventions/Control_2 - No concomitant use of Kampo medicine
Eligibility:
Age-lower limit - 20
years-old
Gender - Male and Female
Key inclusion criteria - Patients with unresectable advanced thyroid cancer who initiated lenvatinib therapy at Ito Hospital between May 1, 2015, and December 31, 2019
Key exclusion criteria - Consent for this study could not be obtained
Target Size - 74
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2022 Year 11 Month 10 Day
Date of IRB - 2022 Year 12 Month 26 Day
Anticipated trial start date - 2023 Year 01 Month 01 Day
Last follow-up date - 2026 Year 03 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069478
Disclaimer: Curated by HT Syndication.
